Amicus Reports Positive Phase II Findings For Fabry Disease Candidate Amigal
This article was originally published in The Pink Sheet Daily
Executive Summary
Migalastat probably is approvable, but the threat to Genzyme’s Fabrazyme is still nominal, analysts say.